VTVT - vTvセラピュ―ティクス （vTv Therapeutics Inc.）

vTv Therapeutics (VTVT) has appointed biotech industry veteran Steven Tuch as CFO, effective immediately.Tuch has over 20 years of financial and business development experience…

vTv Therapeutics Inc Earnings in line, Revenue Beats In Q3

vTv Therapeutics press release (VTVT): Q3 GAAP EPS of -$0.05.The Company’s cash position as of September 30, 2022, was $15.3 million compared to $13.4 million as of December 31, 2021.

HIGH POINT, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.

Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the Board of Directors Agreements with CinRx Pharma and a subsidiary to provide additional capital and access to CinRx’s industry and clinical trial expertise […]

vTv Therapeutics Inc - Class A (VTVT) shares closed today at 0.4% above its 52 week low of $0.95, giving the company a market cap of $63M. The stock is currently down 49.1% year-to-date, down 52.4% over the past 12 months, and down 81.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 48.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 378.6% The company's stock price performance over the past 12 months lags the peer average by 441.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

vTv Therapeutics Inc - Class A (VTVT) shares closed today at 1.9% above its 52 week low of $1.05, giving the company a market cap of $71M. The stock is currently down 42.5% year-to-date, down 49.3% over the past 12 months, and down 80.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 2.0%. Trading Activity Trading volume this week was 11.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 240.8% The company's stock price performance over the past 12 months lags the peer average by 247.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

vTv Therapeutics Inc (NASDAQ: VTVT ) has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here . As a part of the restructuring, the company will reduce its workforce by approximately 65%. The company Full story available on Benzinga.com

Northern Trust Corp decreased its holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) by 75.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,577 shares of the biotechnology companys stock after selling 122,545 shares during the quarter. Northern Trust Corp owned about 0.05% of []

-Workforce reduction of 65%

Zacks Investment Research cut shares of vTv Therapeutics (NASDAQ:VTVT) from a strong-buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical []

HIGH POINT, N.C., Oct. 20, 2021 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that Deepa Prasad will lead the company as

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Essential Things For: vTv Therapeutics Inc. (NASDAQ:VTVT -3.87%), KE Holdings Inc. (NYSE:BEKE 0.97%) appeared first on Stocks Equity .